{
  "abstract": "Objective This study evaluated the efficacy and safety of epcoritamab in real-world clinical practice. Methods Data of 19 patients who received epcoritamab at Saitama Cancer Center were retrospectively analyzed. Results The median follow-up duration was 5.6 months. The overall response rate (ORR) was 73.7%, with a complete response (CR) rate of 47.4%. The ORR in patients with prior exposure to bendamustine was 64.3% (CR rate, 50%), and that of bendamustine-naïve was 100% (CR rate, 40%). The ORR in patients with a bendamustine-free period of ≤6 months was 42.9% (CR rate, 28.6%), while that of patients with a bendamustine-free period of >6 months was 85.7% (CR rate, 71.4%). The median progression-free survival (PFS) and overall survival (OS) have not yet been determined, but the values prior to exposure to bendamustine were 6.6 and 7.6 months, respectively. A comparison between the prior bendamustine exposure and naïve groups showed no significant differences in the PFS and OS. In patients with lactate dehydrogenase (LDH) levels of ≤303 U/L at the start of epcoritamab, the median PFS and OS were not yet reached, while in those with LDH levels of >303 U/L, the median PFS and OS were 2.3 and 3.0 months, respectively. Treatment-emergent adverse events (TEAEs) of grade ≥3 severity occurred in 18 of the 19 patients (94.7%), and in 2 of the 19 patients (10.5%), the emergence of TEAEs necessitated treatment discontinuation. Cytomegalovirus (CMV) reactivation occurred in 11 patients (57.9%). Conclusion Careful attention should be paid to aggressive cases and those with CMV reactivation.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 19,
  "authors": [
    {
      "name": "Yasunobu Sekiguchi"
    },
    {
      "name": "Shizuka Hamano"
    },
    {
      "name": "Kosuke Arai"
    },
    {
      "name": "Hiroki Tsutsumi"
    },
    {
      "name": "Masahisa Kudo"
    },
    {
      "name": "Nobuo Maseki"
    },
    {
      "name": "Yoshie Iizaki"
    },
    {
      "name": "Machiko Kawamura"
    },
    {
      "name": "Kazuhiko Kobayashi"
    },
    {
      "name": "Yu Nishimura"
    },
    {
      "name": "Hiroaki Kanda"
    },
    {
      "name": "Daisuke Takei"
    },
    {
      "name": "Tomoya Abe"
    },
    {
      "name": "Makoto Hanai"
    },
    {
      "name": "Sayaka Endo"
    },
    {
      "name": "Yu Kakusaka"
    },
    {
      "name": "Toshiaki Nakayama"
    },
    {
      "name": "Yasumasa Shimano"
    },
    {
      "name": "Hirofumi Kobayashi"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8yfbn71zp5p6p.bib",
  "cited_by": 0,
  "doi": "10.2169/internalmedicine.6396-25",
  "fulltext_url": "https://www.jstage.jst.go.jp/article/internalmedicine/65/15/65_6396-25/_article",
  "id": "8yfbn71zp5p6p",
  "issns": [
    "1349-7235",
    "0918-2918"
  ],
  "landing_url": "https://www.jstage.jst.go.jp/article/internalmedicine/65/15/65_6396-25/_article",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "jstage-journal",
      "medicine/general"
    ],
    [
      "openalex",
      "2716|Chronic Lymphocytic Leukemia Research"
    ]
  ],
  "openalex": "W4417209197",
  "pdf_url": "https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_6396-25/_pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-08-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/8yfbn71zp5p6p.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:31Z",
      "native_id": "10.2169/internalmedicine.6396-25",
      "source": "jstage",
      "url": "https://www.jstage.jst.go.jp/article/internalmedicine/65/15/65_6396-25/_article"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2716|Chronic Lymphocytic Leukemia Research",
      "subfield": "human-genetics"
    }
  ],
  "title": "A Retrospective Study of the Efficacy and Safety of Epcoritamab in Real-world Clinical Practice: An Analysis of 19 Cases from a Single Institution",
  "title_text": "A Retrospective Study of the Efficacy and Safety of Epcoritamab in Real-world Clinical Practice: An Analysis of 19 Cases from a Single Institution",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:31Z",
  "url": "https://research.draconitic.com/paper/8yfbn71zp5p6p",
  "venue": "Internal Medicine",
  "versions": []
}